$72.48
0.54% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Stock price

$72.48
-4.63 6.00% 1M
+45.16 165.30% 6M
+41.49 133.88% YTD
+46.58 179.85% 1Y
+44.55 159.51% 3Y
+54.21 296.72% 5Y
+58.97 436.49% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.39 0.54%
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Key metrics

Market capitalization $12.52b
Enterprise Value $12.66b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 38.51
P/S ratio (TTM) P/S ratio 38.11
P/B ratio (TTM) P/B ratio 312.87
Revenue growth (TTM) Revenue growth 21.94%
Revenue (TTM) Revenue $328.61m
EBIT (operating result TTM) EBIT $-643.85m
Free Cash Flow (TTM) Free Cash Flow $-589.39m
Cash position $1.25b
EPS (TTM) EPS $-5.40
P/E forward negative
P/S forward 35.04
EV/Sales forward 35.41
Short interest 7.21%
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Insmed Incorporated forecast:

17x Buy
100%

Analyst Opinions

17 Analysts have issued a Insmed Incorporated forecast:

Buy
100%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
329 329
22% 22%
100%
- Direct Costs 79 79
27% 27%
24%
250 250
20% 20%
76%
- Selling and Administrative Expenses 368 368
25% 25%
112%
- Research and Development Expense 514 514
6% 6%
156%
-632 -632
1% 1%
-192%
- Depreciation and Amortization 12 12
40% 40%
4%
EBIT (Operating Income) EBIT -644 -644
2% 2%
-196%
Net Profit -803 -803
15% 15%
-244%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Positive
Schaeffers Research
17 days ago
Subscribers to  Chart of the Week  received this commentary on Sunday, September 8.
Neutral
PRNewsWire
22 days ago
BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees.
Positive
Seeking Alpha
about one month ago
Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pending regulatory approval in Q4 2024. Insmed's R&D expenses were $146.7 million in Q2 2024, down from the previous year due to prior non-cash acquisition costs.
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 912
Founded 1988
Website www.insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today